Closing Reflections on Evolving Practices for Bispecific Administration
Brooke Peters, PharmD, BCOP, offers a closing reflection on the transition from inpatient to outpatient treatment of bispecific antibodies.
Advancing Clinical Practices for Administration of Bispecifics
A discussion on the evolving practices for administering bispecific T-cell engagers, from academic to community centers.
Identifying and Mitigating Late Adverse Events
Dr. Peters shares clinical considerations for administering bispecifics, emphasizing the identification and mitigation strategies of late adverse events.
Grading and Management of Early Adverse Events
Expert regional community oncologist examines the grading and management of early adverse events such as CRS and ICANS, discussing the national guidelines that are utilized.
Exploring the Roles and Responsibilities of Bispecific Administration Programs
Expanding on the roles and responsibilities for executing a bispecifics administration program, highlighting a multidisciplinary collaboration to establish SOPs, training, and education.
Executing Program Development and SOPs for Bispecific T-cell Engagers
Dr. Peters shares her experience in SOPs and program development for administration of bispecific T-cell engagers, noting program champions and key program components.
An Overview of Institution-Led Programs for Bispecific Engager Administration
Brooke Peters, PharmD, BCOP, provides a comprehensive overview of her institution’s bispecifics administration program, highlighting several agents and the hematologic/oncologic conditions they treat.
